Postdoctoral Fellow in the Quantitative Study of Alternative mRNA Splicing

Posted on December 8,

Justin B. Kinney and Adrian R. Krainer seek a postdoctoral fellow to spearhead a project focused on quantitative signal integration in alternative mRNA splicing. This position is part of an ongoing collaboration between the Kinney Lab and Krainer Lab, the goal of which is to understand the readout of pre-mRNA sequence by snRNPs and RBPs, as well as the effects of splice-modifying drugs. The successful candidate will be expected to help design their project’s aims and to lead the necessary experimental work. These studies will primarily focus on splicing in human cell culture and/or in vitro splicing reactions, and will involve a combination of both low-throughput and high-throughput techniques, including massively parallel reporter assays (MPRAs). Novel experimental techniques will be developed as needed.

Both the Kinney Lab and Krainer Lab are situated on the beautiful main campus of Cold Spring Harbor Laboratory (CSHL). CSHL is a world-renowned non-profit research institution that is home to eight Nobel Prize winners and consistently ranks among the world’s top institutions in research impact per scientist. Members of the CSHL community benefit from the vibrant Meetings and Courses program, which hosts leading conferences in many biological disciplines. CSHL is located on the north shore of Long Island and is readily accessible from New York City via the Long Island Rail Road.

The Kinney Lab develops experimental, computational, and mathematical approaches for deciphering the biophysical mechanisms of gene regulation. The primary biological goal of their research is to quantitatively understand the mechanisms of alternative mRNA splicing, as well as the effects of splice-modifying drugs for treating human disease. Their experimental work centers on the use of MPRAs, a technology that Dr. Kinney and his lab have pioneered and continue to advance. They also develop machine learning approaches, including deep learning strategies, for extracting quantitative models of sequence-function relationships from MPRA datasets and for interpreting these models in terms of underlying biophysical mechanisms. Please visit for more information.

The Krainer Lab has pioneered the mechanistic study of alternative mRNA splicing as well as the development of splice-modifying therapeutics for treating disease. In addition to discovering the first alternative splicing factor (SRSF1), Dr. Krainer and his lab developed nusinersen (Spinraza®), the first FDA-approved drug for correcting a splicing defect. Dr. Krainer is a member of the National Academy of Sciences and has received numerous awards, including the 2019 Breakthrough Prize and 2021 Wolf Prize. His lab continues to pursue fundamental mechanistic studies of alternative mRNA splicing, as well as develop antisense oligonucleotide therapeutics for treating a wide range of diseases. Please visit for more information.

Qualifications: Candidates must have (or soon receive) a PhD in Molecular Biology, Biochemistry, Genetics, Bioengineering, Biophysics, or related field. Candidates must also have a track record of successful experimental work, as well as one or more first-author research publications and/or pre-prints in the field of RNA processing. Candidates should have strong written and oral communication skills, the ability to navigate and synthesize relevant research literature, and the ability to develop and troubleshoot new experimental approaches when needed. Familiarity with mammalian cell culture, in vitro splicing reactions, the computational analysis of biological sequence data, public genomic databases, and Python programming is a plus.

To apply: Interested candidates should email Dr. Kinney ([email protected]) and Dr. Krainer ([email protected]) to briefly explain why they are interested in this position. Promising candidates will then be encouraged to formally apply via the CSHL careers website and to provide a cover letter, CV, and contact information for two individuals who can supply letters of reference. Please do not hesitate to reach out by email if you have any questions. Potential applicants should inquire about this position by 31 January 2022.

CSHL is an EO/AA Employer. All qualified applicants will receive consideration for employment and will not be discriminated against on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, age, disability or protected veteran status. VEVRAA Federal Contractor.